Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 21 h ago

Attovia Therapeutics, Inc.: venBio Global Strategic Fund IV, L.P. discloses a stake of more than 5% (Schedule 13G)

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

venBio Global Strategic Fund IV, L.P. disclosed a stake exceeding 5% in Attovia Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0000905148-26-004977). The filing signals that venBio has crossed the 5% beneficial ownership threshold, making it a reportable large holder in the company. The exact number of shares and percentage were not specified in the headline disclosure. Investors will watch for further detail in the full filing, including the precise share count and any indication of passive versus active intent.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Attovia Therapeutics, Inc., venBio Global Strategic Fund IV, L.P.